Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder;...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is of fair value on EV/EBITDA.
Target Price
The average target price of LPGO.ST is 0.01 and suggests 22% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to
Buy
Sell